Omalizumab reduces corticosteroid use in patients with severe allergic asthma: Real-life experience in israel

Journal of Asthma

Volumn 49, Issue 1, 2012, Pages 78-82

  Rottem, Menachem ^a,b  

^a HAEMEK MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

allergy; corticosteroids; hospital admissions; IgE; immunoglobulin E; rhinitis; xolair

Indexed keywords

BETAMETHASONE DIPROPIONATE; CORTICOSTEROID; IMMUNOGLOBULIN E ANTIBODY; LEUKOTRIENE RECEPTOR BLOCKING AGENT; OMALIZUMAB; PREDNISONE; THEOPHYLLINE;

ADD ON THERAPY; ADULT; AGED; ALLERGIC ASTHMA; ARTICLE; CLINICAL ARTICLE; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; EMERGENCY WARD; FEMALE; HUMAN; INJECTION SITE REACTION; ISRAEL; MALE; PATIENT SELECTION; RETROSPECTIVE STUDY; TREATMENT DURATION;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERSENSITIVITY; ISRAEL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84855830702     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770903.2011.637598     Document Type: Article

References (29)

1. Anandan C, Nurmatov U, van Schayck OC, Sheikh A. Is the prevalence of asthma declining? Systematic review of epidemiological studies. Allergy 2010;65(2):152-167.
2. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, Gibson P, Ohta K, O Byrne P, Pedersen SE, Pizzichini E, Sullivan SD, Wenzel SE, Zar HJ. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008;31(1):143-178.
3. Holt PG, Macaubas C, Stumbles PA, Sly PD. The role of allergy in the development of asthma. Nature 1999;402(6760 Suppl):B12-B17.
4. Busse W, Corren J, Lanier BQ,McAlary M, Fowler-Taylor A, Cioppa D, van As A, Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-190. (Pubitemid 32735398)
5. Solèr M, Matz J, Townley R, Buhl R, O Brien J, Fox H, Thirlwell J, Gupta N, Della Cioppa G. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254-261. (Pubitemid 32776398)
6. Buhl R, Solèr M, Matz J, Townley R, O Brien J, Noga O, Champain K, Fox H, Thirlwell J, Della Cioppa G. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002;20: 73-78. (Pubitemid 34822924)
7. Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 2003;91:154-159.2 (Pubitemid 36999474)
8. Holgate ST, Chuchalin AG, Hébert J, Lötvall J, Persson GB, Chung KF, Bousquet J, Kerstjens HA, Fox H, Thirlwell J, Cioppa GD. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34:632-638. (Pubitemid 38534897)
9. Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004;59:701-708. (Pubitemid 38850344)
10. Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, Fox H, Surrey K. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;59:709-717. (Pubitemid 38850345)
11. Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60: 309-316. (Pubitemid 40293346)
12. Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, Fox H, Hedgecock S, Blogg M, Cioppa GD. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60:302-308. (Pubitemid 40293345)
13. Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, Gruchalla RS, Kattan M, Teach SJ, Pongracic JA, Chmiel JF, Steinbach SF, Calatroni A, Togias A, Thompson KM, Szefler SJ, Sorkness CA. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011;364:1005-1015.
14. MolimardM, de Blay F, Didier A, Le Gros V. Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med 2008;102(1):71-76. (Pubitemid 350161845)
15. Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe A, Pilette C, Lee CS, Gurdain S, Vancayzeele S, Lecomte P, Hermans C, MacDonald K, Song M, Abraham I. Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med 2009;103(11):1633- 1642.
16. Korn S, Thielen A, Seyfried S, Taube C, Kornmann O, Buhl R. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med 2009;103(11):1725-1731.
17. Molimard M, Buhl R, Niven R, Le Gros V, Thielen A, Thirlwell J, Maykut R, Peachey G. Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data. Respir Med 2010;104(9):1381-1385.
18. Cazzola M, Camiciottoli G, Bonavia M, Gulotta C, Ravazzi A, Alessandrini A, Caiaffa MF, Berra A, Schino P, Di Napoli PL, Maselli R, Pelaia G, Bucchioni E, Paggiaro PL, Macchia L. Italian real-life experience of omalizumab. Respir Med 2010;104(10):1410-1416.
19. Korn S, Schumann C, Kropf C, Stoiber K, Thielen A, Taube C, Buhl R. Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma. Ann Allergy Asthma Immunol 2010;105: 313-319.
20. Kardos P, Wittchen HU, Mühlig S, Ritz T, Buhl R, Rabe K, Klotsche J, Riedel O; for the sap-NEEDS study group. Controlled and uncontrolled allergic asthma in routine respiratory specialist care-a clinicalepidemiological study in Germany. Curr Med Res Opin 2011;27(9): 1835-1847.
21. Schumann C, Kropf C, Wibmer T, Rüdiger S, Stoiber KM, Thielen A, Rottbauer W, Kroegel C. Omalizumab in patients with severe asthma: The XCLUSIVE Study. Clin Respir J 2011; doi: 10.1111/j.1752- 699X.2011.00263.x. [Epub ahead of print].
22. National Asthma Education and Prevention Program. Expert panel report 3 guidelines for the diagnosis and management of asthma. US Department of Health and Human Services, National Institute of Health, National Heart, Lung and Blood Institute. 2007.
23. Sthoeger ZM, Eliraz A, Asher I, Berkman N, Elbirt D. Beneficial effects of Xolair® (Omalizumab) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available treatment (GINA 2002 step IV)-The Israeli Arm of the INNOVATE Study. IMAJ 2007;9:472-475. (Pubitemid 46991492)
24. Bousquet J, Rabe K, Humbert M, Chung KF, Berger W, Fox H, Ayre G, Chen H, Thomas K, Blogg M, Holgate S. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007;101(7):1483-1492. (Pubitemid 46850589)
25. Peters SP, Ferguson G, Deniz Y, Reisner C. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med 2006;100:1139-1151. (Pubitemid 43793051)
26. Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V, Kovac SH, Spettell CM, Saag KG. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 2006;55:420-426. (Pubitemid 43887028)
27. Wechsler ME, Kelley JM, Boyd IO, Dutile S, Marigowda G, Kirsch I, Israel E, Kaptchuk TJ. Active albuterol or placebo, sham acupuncture, or no intervention in asthma. N Engl J Med 2011;365:119-126.
28. Bahadori K, Quon BS, Doyle-Waters MM, Marra C, Fitzgerald JM. A systematic review of economic evaluations of therapy in asthma. J Asthma Allergy 2010;13(3):33-42.
29. Nopp A, Johansson SG, Ankerst J, Palmqvist M, Oman H. CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment. Allergy 2007;62(10):1175-1181. (Pubitemid 47374025)